Gagliani Luiz Henrique, Alkmim Maia Wagner T, Sá-Filho Dercy, Janini Luiz Mario, Sucupira Maria Cecilia, Caseiro Marcos Montani, Diaz Ricardo Sobhie
Federal University of São Paulo, Brazil.
AIDS Res Hum Retroviruses. 2011 Mar;27(3):251-6. doi: 10.1089/aid.2010.0150. Epub 2010 Oct 26.
Santos is a Brazilian port city with high HIV incidence, high primary antiretroviral resistance levels, high HIV-1 BF recombinants prevalence, and high rates of antiretroviral virologic failure. We evaluated factors related to virologic failure after 48 weeks of HAART in this population. We compared demographic and HIV profiles among 43 individuals with virologic failure (group 1) and 37 with virologic success (group 2) after 48 weeks of HAART initiation. The overall primary antiretroviral resistance prevalence was 31.2%; 46.5% in group 1 and 13.5% in group 2 (p < 0.005). Nine patients from group 1 and seven from group 2 were infected by F or BF strains. Fifteen individuals presented with NRTI mutations, 13 with NNRTI mutations, three with PI mutations, and five with NRTI and NNRTI mutations. No significant differences were observed in baseline viral load, CD4, clade assignment, antiretrovirals used, or demographics among groups or patients harboring resistant versus wild-type viruses. In this region, there was a high prevalence of antiretroviral resistance among long standing infected patients whose disease had progressed. This finding supports the concept that resistance testing prior to ART initiation is cost effective. The association between primary antiretroviral resistance and virologic failure may suggest that primary resistance greatly impairs antiretroviral activity.
桑托斯是巴西的一个港口城市,艾滋病病毒(HIV)发病率高、一线抗逆转录病毒药物耐药水平高、HIV-1 BF重组毒株流行率高,且抗逆转录病毒治疗的病毒学失败率高。我们评估了该人群接受高效抗逆转录病毒治疗(HAART)48周后与病毒学失败相关的因素。我们比较了43例病毒学失败患者(第1组)和37例HAART启动48周后病毒学治疗成功患者(第2组)的人口统计学和HIV特征。总体一线抗逆转录病毒药物耐药流行率为31.2%;第1组为46.5%,第2组为13.5%(p<0.005)。第1组有9例患者和第2组有7例患者感染了F或BF毒株。15例患者出现核苷类逆转录酶抑制剂(NRTI)突变,13例出现非核苷类逆转录酶抑制剂(NNRTI)突变,3例出现蛋白酶抑制剂(PI)突变,5例同时出现NRTI和NNRTI突变。在基线病毒载量、CD4细胞计数、分支分类、使用的抗逆转录病毒药物或人口统计学方面,耐药病毒组与野生型病毒组之间或两组患者之间均未观察到显著差异。在该地区,疾病进展的长期感染患者中抗逆转录病毒药物耐药的流行率很高。这一发现支持了在开始抗逆转录病毒治疗之前进行耐药检测具有成本效益的观点。一线抗逆转录病毒药物耐药与病毒学失败之间的关联可能表明,原发性耐药极大地损害了抗逆转录病毒活性。